Thrombin generation assay: a useful routine check‐up tool in the management of patients with haemophilia?
- 15 January 2009
- journal article
- Published by Wiley in Haemophilia
- Vol. 15 (1) , 290-296
Abstract
Summary. Severity assessment of patients with haemophilia A (HA) is traditionally based on FVIII activity (FVIII:C). Clinical phenotype of HA patients often differs between individuals with the same FVIII:C determined with clotting and chromogenic assays. The aim of this study was to assess the influence of the FVIII:C on thrombin generation (TG) assay parameters both in vitro and ex‐vivo postinfusion plasma. For in‐vitro approach, influence of FVIII:C was evaluated on TG parameters in several dilutions of a normal plasma pool with commercial FVIII‐depleted‐plasma (FVIIIDP) and in others experiments, adding increasing amounts of different commercial FVIII concentrates (Fanhdi, Haemate‐P, Hemofil‐M and Kogenate Bayer) to FVIIIDP. In a series of 50 postinfusion samples, from HA patients of different severity, we assayed TG and FVIII:C (chromogenic and clotting). In vitro experiments, the 50% of maximum TG peak (TGMP) was achieved using only 5% FVIII:C and the TGMP was obtained with 40% of normal VIII:C. Impaired response compared with normal plasma was found in FVIIIDP using addition of increasing amounts of different commercial FVIII concentrates. An overall good correlation between the two FVIII assays was observed (y = 0.9115x − 0.273, r = 0.975, P < 0.001); TGMP and the Lag‐Phase‐Time (LPT) provided some discrepant results when compared with the total range of FVIII:C measurements. In contrast, correlations for TGMP, LPT and endogenous thrombin potential were improved in samples restricted to FVIII:C <5%. We conclude that TG parameters tentatively could be a tool to tailor the global haemostatic capacity in haemophilic patients.Keywords
This publication has 25 references indexed in Scilit:
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Phenotypic heterogeneity in severe hemophiliaJournal of Thrombosis and Haemostasis, 2007
- Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generationHaemophilia, 2006
- Thrombin generation and phenotypic correlation in haemophilia AHaemophilia, 2005
- Factor VIII Inhibitor-Bypassing Agents Act by Inducing Thrombin Generation and Can Be Monitored by a Thrombin Generation AssayPathophysiology of Haemostasis and Thrombosis, 2003
- First and Second Generation Recombinant Factor VIII Concentrates in Previously Untreated Patients: Recovery, Safety, Efficacy, and Inhibitor DevelopmentSeminars in Thrombosis and Hemostasis, 2002
- Issues with the Assay of Factor VIII Activity in Plasma and Factor VIII ConcentratesThrombosis and Haemostasis, 2000
- Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparationsHaemophilia, 1996
- Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and BJournal of Internal Medicine, 1992
- Pharmacokinetic Properties of Recombinant Factor VIII Compared with a Monoclonally Purified Concentrate (Hemofil® M)Thrombosis and Haemostasis, 1992